Swiss Medica’s O24 Chosen for Clinical Study

TORONTO, Canada – Swiss Medica Inc. (OTC:SWME), a company involved in the commercialization of proprietary bioscience products aimed at relieving chronic ailments, announced today that Dr. Gordon Ko, medical director for the Canadian Centre for Integrated Medicine and lecturer at of Sunnybrook and Women’s College Health Centre in Toronto, will be conducting a clinical study using Swiss Medica’s flagship product, called O24. Dr. Ko will be testing O24’s effect on fibromyalgia, a chronic condition causing pain, stiffness and tenderness of the muscles, tendons and joints. He will be assisted by fibromyalgia specialist Iris Weverman, a registered physiotherapist, owner of the Dorothy Madgett Physiotherapy and Stress Management Clinic and the Iris Weverman Physiotherapy Clinic. The study will begin in June and run for approximately 45 days.

“We are extremely excited to be working with Ko and Weverman,” said Grant Johnson, President and COO of Swiss Medica. “We already have the backing of European clinical trials, but we just recently began the North American launch of our all natural topical analgesic, O24. Now we’d like to get some North American clinical trial proof.”

The results of the study will be published by Dr. Ko and may lead to a larger randomized control trial in the future at Sunnybrook and Women’s College Health Centre.

“O24 is currently being used for pain associated with inflammatory diseases like arthritis. I think it may be a safe treatment option for managing this chronic pain syndrome,” said Dr. Ko.

“I have a special interest in fibromyalgia and chronic myofascial patients.
O24 was brought to my attention by my patients. I have found a product that would be very helpful for my chronic pain patients”, said Ms. Weverman.

This is the second study on O24’s effects on fibromyalgia. The first study was done in Germany in 2000 and was published by Dr. Eckart W. Freidl, Medical Director, Klinikum Bad Bocklet.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at and

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.